Metabolic and Clinical Outcomes in Type 1 Diabetes in the COVID-19 Pre- and Post-Vaccination Periods in Spain: The COVID-SED1 Study
Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10045/142103
Título: | Metabolic and Clinical Outcomes in Type 1 Diabetes in the COVID-19 Pre- and Post-Vaccination Periods in Spain: The COVID-SED1 Study |
---|---|
Autor/es: | Gómez-Peralta, Fernando | Menéndez, Edelmiro | Conde, Santiago | Abellán-Galiana, Pablo | Brito, Miguel | Beléndez, Marina | Pérez, Antonio |
Grupo/s de investigación o GITE: | Psicología Social y Salud (PSS) |
Centro, Departamento o Servicio: | Universidad de Alicante. Departamento de Comunicación y Psicología Social |
Palabras clave: | Type 1 diabetes | COVID-19 | Vaccination | Glycemic control | Continuous glucose monitoring | Diabetes complications |
Fecha de publicación: | 26-mar-2024 |
Editor: | MDPI |
Cita bibliográfica: | Journal of Clinical Medicine. 2024, 13(7): 1922. https://doi.org/10.3390/jcm13071922 |
Resumen: | Aims: To evaluate the metabolic and clinical outcomes in the Spanish type 1 diabetes mellitus (T1D) population before and after COVID-19 vaccination. Methods: A retrospective observational study was carried out in Spanish public hospitals previously enrolled in the SED1 study. Adults and children with T1D were included and their clinical electronic records were reviewed. Clinical, laboratory, and glucometric parameters from continuous glucose monitoring (CGM) data corresponding to the periods before and after administering the first COVID-19 vaccination were analyzed. Results: A total of 26 centers and 228 patients participated in this new phase of the SED1 study and 187 were finally evaluable (mean age 37.5 ± 15.6 years, 56.7% women). Overall, 94.6% of the sample was vaccinated, and this percentage increased with higher levels of education (p-value = 0.027). In the pre- and post-vaccination periods, respectively, the number of patients with acute hyperglycemic decompensation was 6/161 (3.7%) and 7/161 (4.3%) (p = 1) and with acute hypoglycemic decompensation was 6/161 (3.7%) and 6/161 (3.7%) (p = 1). The HbA1c level was lower in the post-vaccination period(mean ± SD, mg/dL): pre-vaccination 7.4 ± 0.9; post-vaccination 7.2 ± 1.0, (−0.19; p-value = 0.0006). A total of 31.9% of patients (95% CI: 24.7–39.7) in the pre-vaccination period and 45.0% (IC95%: 37.1–53.1) in the post-vaccine period had HbA1c < 7% (p-value < 0.001). Glucometrics from CGM data also showed numerical improvements post-vaccination. Conclusions: The COVID-19 vaccination was highly accepted in the Spanish T1D population, with hesitancy about the COVID-19 vaccine being higher in those with lower educational levels. A mildly better glycemic control was observed in the post-vaccination period. |
Patrocinador/es: | The study was funded by Sanofi through an unrestricted grant to the Spanish Diabetes Society (SED) (Sanofi Spain PC-2020-13146). |
URI: | http://hdl.handle.net/10045/142103 |
ISSN: | 2077-0383 |
DOI: | 10.3390/jcm13071922 |
Idioma: | eng |
Tipo: | info:eu-repo/semantics/article |
Derechos: | © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
Revisión científica: | si |
Versión del editor: | https://doi.org/10.3390/jcm13071922 |
Aparece en las colecciones: | INV - PSS - Artículos de Revistas |
Archivos en este ítem:
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Gomez-Peralta_etal_2024_JClinMed.pdf | 258,01 kB | Adobe PDF | Abrir Vista previa | |
Todos los documentos en RUA están protegidos por derechos de autor. Algunos derechos reservados.